Clinical support materials

AMPLIFY Clinical Trial Summary

A summary of the AMPLIFY trial - a fixed-duration combination in 1L CLL.

Found this useful? You might also be interested in:

 

CLL Exchange Bite-sized:
Fixed-duration decision making
in 1L CLL

BSH Guidelines 2025
for the 1L Treatment of CL

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

September 2025 I GB-69434